Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced an e-poster presentation by Thomas Crawford, M.D., on the design of the company’s ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at … [Read more…]